BioCardia receives US Patent covering a method of producing mesenchymal stem cells using a single patient donor for both source cells and culture medium
May 9, 2016
SAN CARLOS, CA – BioCardia®, Inc., a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, with clinical programs in heart failure and sub-acute infarction, today announced the issuance of United States Patent No. 9,301,975 relating to a method of producing cells cultured in media derived from a single human donor.
Dr. Peter Altman, CEO of BioCardia: “We are pleased to have obtained this new patent. To our knowledge, this is the first patent covering a method of producing mesenchymal cells from a single donor for cells and culture medium. This contributes to the more than 75 issued patents related to cardiovascular regenerative medicine to which BioCardia has either exclusive or nonexclusive rights.”
Dr. Eric Duckers, CMO of BioCardia: “This may open new pathways for allogenic dosage forms that address the problems of expansion of cells to enable large numbers of patients to be treated, lot to lot variability of culture media, and immune responses to allogenic cells. The patent specification also contains details on the use of transcriptome wide gene expression profiling for the development of companion diagnostics for autologous cell based therapies to maximize the probability of clinical success.”